BRAF and small cell lung carcinoma: In particular, FGF-2 was shown to promote drug resistance of small cell lung cancer (SCLC) cells through the formation of a multi-protein complex comprising protein kinase C (PKC) ε, v-raf murine sarcoma viral oncogene homolog B1 (B-RAF) and p70 S6 kinase β (S6K2).